Walk, Roger A.

From: Sent: To:


Stern, Warren [Warren Stern@parexel.com]

Friday, July 14, 2000 2:15 PM 'ROGERWALK@YAHOO.com'

Steuernagel, Carl; Roethig, Hans-Juergen

Cc: Subject:

BIOMARKER STRATEGIES





Dr. Roger Walk

Director Worldwide Scientific Affairs Philip-Morris PO Box 2361 Richmond, VA 23261

Dear Dr. Walk:

Parexel has recently concluded an alliance with a Massachusetts based company, MassTrace, which specializes in the use of biomarkers in human clinical trials. While their main orientation is the use of biomarkers in drug related clinical trials, the knowledge they have gained from many years of thinking and working on these issues, and, from the standpoint of selecting practical assays which provide noninvasive indices of enzymatic activity in patients or normal volunteers may be useful to Philip-Morris. Since MassTrace is bound by a secrecy agreement to Parexel, I took the liberty of seeking their expert opinion regarding the biomarker strategy for the smoking study being designed by Philip-Morris and collaborators. The comments and suggestions of the MassTrace biomarker experts are provided in the attachment.

If you would like to meet with their lead scientist, Dr. Alfred Ajami, to review the thoughts given in their proposal, or to discuss other matters relative to the biomarker strategy, we would be please to set up a meeting.

Best regards.

Warren Stern, PhD Sr. Vice President Scientific and Medical Services

cc: P. Leone, A. Ajami (MassTrace) C. Steuernagel H-J. Roethig, MD